Genmab — September 2016
-
A serious adverse event (SAE) in human drug trials is defined as any untoward medical occurrence that at any dose
results in death,
is life-threatening
requires inpatient hospitalization or causes prolongation of existing hospitalization
results in persistent or significant disability/incapacity,
is a congenital anomaly/birth defect, or
requires intervention to prevent permanent impairment or damage.[1] -
Det kan være interaktion med andre lægemidler som kan være årsagen. Den slags er også vigtigt at få styr på.
-
http://medwatch.dk/secure/Medicinal___Biotek/article9010301.ece Så har J&J brugt penge!
-
Ang: SAE. Er det ikke netop formålet med studiet (altså at nå frem til, hvad der kan udløse en SAE)?
-
Glæder mig allerede til beskos's indslag på Børsen play
det bliver nok underholdende som altid..... -
Michael Pehl - Celgene - er glad for Pollux: If you go for the combination of Revlimid, dexamethasone and daratumumab, the data that has been shown points to a progression-free survival estimate of 40 to 50 months. And you can actually really imagine that this is a big driver for the treatment duration and for the appreciation of Revlimid. http://www.investorvillage.com/smbd.asp?mb=341&mn=206353&pt=msg&mid=16371394
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind